Substituting Doxorubicin with Nonpegylated Liposomal Doxorubicin for the Treatment of Early Breast Cancer: Results of a Retrospective Study

Table 2

Mean (±standard error) LVEF (%) values according to timing of NPLD, regimen used, and age at diagnosis.

		Baseline	During	≤4 months after chemotherapy ended	5–8 months after chemotherapy ended	9–12 months after chemotherapy ended	>12 months after chemotherapy ended
NPLD timing	Adjuvant	63.9±0.7; (𝑛=60)	64.8±0.8; (𝑛=33)	63.4±1.3; (𝑛=31)	64.8±1.7; (𝑛=11)	62.8±1.6; (𝑛=4)	64.1±1.6; (𝑛=8)
	Primary	65.1±1.3; (𝑛=17)	63.0±1.6; (𝑛=8)	63.3±1.5; (𝑛=6)	63.8±2.8; (𝑛=6)	No data	68.5±1.5; (𝑛=2)
NPLD regimen	AC + T	63.8±0.7; (𝑛=59)	63.9±0.8; (𝑛=27)	63.3±1.3; (𝑛=29)	64.7±1.5; (𝑛=12)	63.7±1.9; (𝑛=3)	64.6±1.7; (𝑛=7)
	TAC	66.1±1.5; (𝑛=14)	65.4±1.7; (𝑛=12)	63.9±2.0; (𝑛=7)	64.0±3.6; (𝑛=5)	60.0; (𝑛=1)	66.0±3.1; (𝑛=3)
	AC	62.7±2.7; (𝑛=3)	66.0±2.0; (𝑛=2)	60.0; (𝑛=1)	No data	No data	No data
Age at diagnosis	<60	64.0±0.8; (𝑛=53)	65.1±0.8; (𝑛=29)	62.9±1.5; (𝑛=25)	64.0±1.6; (𝑛=15)	62.8±1.6; (𝑛=4)	64.9±1.6; (𝑛=8)
	≥60	64.5±1.0; (𝑛=23)	62.8±1.6; (𝑛=12)	64.3±1.4; (𝑛=12)	68.0±2.0; (𝑛=2)	No data	64.5±2.5; (𝑛=2)

AC: 6 cycles of NPLD (60 mg/m²) and cyclophosphamide (600 mg/m²).
AC + T: 4 cycles of NPLD (60 mg/m²) and cyclophosphamide (600 mg/m²) followed by 4 cycles of docetaxel (75 mg/m²).
TAC: six cycles of NPLD (60 mg/m²) and cyclophosphamide (600 mg/m²) and docetaxel (75 mg/m²).